
==== Front
Mol Cancer Ther
Mol Cancer Ther
Molecular Cancer Therapeutics
1535-7163
1538-8514
American Association for Cancer Research

38670552
MCT-23-0524
10.1158/1535-7163.MCT-23-0524
Version of Record
Biological Agents & Therapies
Immunotherapy
Lung Cancer
Large Molecule Therapeutics
HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
HPN328, a DLL3/CD3 T-Cell Engager to Treat Solid Tumors
https://orcid.org/0009-0006-6766-4006
Molloy Mary E. Harpoon Therapeutics, South San Francisco, California.
*
https://orcid.org/0009-0002-2532-6851
Aaron Wade H. Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0009-0004-7062-6452
Barath Manasi Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0000-0001-8494-1294
Bush Mabel C. Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0000-0002-8842-3475
Callihan Evan C. Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0009-0002-9627-557X
Carlin Kevin Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0000-0002-1875-7920
Cremin Michael Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0009-0007-4500-4792
Evans Thomas Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0009-0001-8639-2775
Guerrero Maria G. Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0009-0003-1886-5483
Hemmati Golzar Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0009-0004-6898-1535
Hundal Avneel S. Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0009-0008-9070-9991
Lao Llewelyn Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0009-0000-3787-9133
Laurie Payton Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0009-0006-9092-6318
Lemon Bryan D. Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0009-0003-6195-3980
Lin S.J. Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0009-0008-6533-469X
O’Rear Jessica Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0009-0006-4699-3812
Patnaik Purbasa Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0009-0001-2903-4795
Sotelo Rocha Sony Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0000-0002-4974-6503
Santiago Linda Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0009-0008-5662-613X
Strobel Kathryn L. Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0009-0005-1481-881X
Valenzuela Laura B. Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0000-0002-1696-8011
Wu Chi-Heng Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0009-0008-1011-4358
Yu Stephen Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0000-0002-0791-1435
Yu Timothy Z. Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0000-0001-6284-3431
Anand Banmeet S. Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0009-0009-0025-1655
Law Che-Leung Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0009-0007-7803-8382
Sun Liping L. Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0009-0006-8683-0428
Wesche Holger Harpoon Therapeutics, South San Francisco, California.

https://orcid.org/0009-0005-4106-9201
Austin Richard J. Harpoon Therapeutics, South San Francisco, California.

* Corresponding Author: Mary E. Molloy, Harpoon Therapeutics, 131 Oyster Point Boulevard, South San Francisco, CA 94080. E-mail: mem.maryellen.molloy@gmail.com
Mol Cancer Ther 2024;23:1294–304

04 9 2024
26 4 2024
23 9 12941304
22 10 2023
17 2 2024
15 4 2024
©2024 The Authors; Published by the American Association for Cancer Research
2024
American Association for Cancer Research
https://creativecommons.org/licenses/by-nc-nd/4.0/ This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

Abstract

Delta-like ligand 3 (DLL3) is expressed in more than 70% of small cell lung cancers (SCLCs) and other neuroendocrine-derived tumor types. SCLC is highly aggressive, and limited therapeutic options lead to poor prognosis for patients. HPN328 is a trispecific T cell–activating construct (TriTAC) consisting of three binding domains: a CD3 binder for T-cell engagement, an albumin binder for half-life extension, and a DLL3 binder for tumor cell engagement. In vitro assays, rodent models, and non-human primates were used to assess the activity of HPN328. HPN328 induces potent dose-dependent killing of DLL3-expressing SCLC cell lines in vitro, concomitant with T-cell activation and cytokine release. In an NCI-H82 xenograft model with established tumors, HPN328 treatment led to T-cell recruitment and anti-tumor activity. In an immunocompetent mouse model expressing a human CD3ε epitope, mice previously treated with HPN328 withstood tumor rechallenge, demonstrating long-term anti-tumor immunity. When repeat doses were administered to cynomolgus monkeys, HPN328 was well tolerated up to 10 mg/kg. Pharmacodynamic changes, such as transient cytokine elevation, were observed, consistent with the expected mechanism of action of T-cell engagers. HPN328 exhibited linear pharmacokinetics in the given dose range with a serum half-life of 78 to 187 hours, supporting weekly or less frequent administration of HPN328 in humans. Preclinical and nonclinical characterization suggests that HPN328 is a highly efficacious, safe, and novel therapeutic candidate. A phase 1/2 clinical trial is currently underway testing safety and efficacy in patients with DLL3-expressing malignancies.

Harpoon Therapeutics http://dx.doi.org/10.13039/
==== Body
pmcIntroduction

Lung cancer is the leading cause of cancer death worldwide (1). Small cell lung cancer (SCLC) represents 15% to 20% of lung cancer diagnoses and is a highly aggressive and lethal form of lung cancer. There is a strong association with SCLC incidence and tobacco exposure (2). Few effective treatment options exist for patients, and the 5-year survival rate is only about 7% (3). The mainstay of treatment for SCLC has been chemotherapy, with checkpoint inhibitors recently approved as frontline treatment in combination with chemotherapy (4). There remains, however, an urgent unmet clinical need for better therapies to treat this disease.

Novel SCLC therapies have targeted DLL3, a single-pass type I transmembrane protein, identified as being overexpressed in cells isolated from small cell lung cancer (SCLC) and large cell neuroendocrine cancer patient-derived xenografts (5). The prevalence of DLL3 expression in SCLC has been reported to be in the range of 68% to 100% (6, 7). In addition to SCLC, DLL3 is also expressed in other malignancies including glioma (8), neuroendocrine prostate cancer (9), gastrointestinal neuroendocrine malignancies (10), and small cell bladder cancer (11). By contrast, healthy adult tissues have shown limited surface expression of DLL3. In normal tissues, expression of DLL3 was detected at very low levels in the brain, pituitary, and pancreatic islets and showed a cytoplasmic staining pattern by IHC (12–14). Based on its elevated expression in tumors and its restricted and low expression in normal tissues, DLL3 has become an attractive target for antibody- and cell-based therapeutics. Modalities exploring DLL3 as a target in research and clinical development include antibody–drug conjugates, CAR T cells, and CD3-based bispecific T cell–engaging molecules (12–16). Objective responses have been reported for the DLL3-targeting antibody–drug conjugate (ADC) rovalpituzumab tesirine (Rova-T; refs. 12 and 14), although a phase 3 trial failed to demonstrate the survival benefit (17). Dose-limiting toxicity of Rova-T seems to be mainly associated with the tesirine payload and not DLL3. Although the clinical development of Rova-T has been discontinued, its anti-tumor activity in patients has provided clinical validation for DLL3 as an attractive target for other targeting modalities.

Here, we describe HPN328, a trispecific T cell–activating construct (TriTAC) targeting DLL3, which is currently being tested in a phase 1 clinical trial for the treatment of SCLC and other DLL3-expressing tumors (NCT04471727). TriTACs are designed to treat solid tumors by overcoming the challenges seen with previous generations of T cell–engaging molecules. They are engineered to have a long serum half-life, small size, and high stability to improve patient safety and solid tumor activity (18, 19). HPN328 consists of a single-domain antibody (sdAb) specific for DLL3, a sdAb specific for serum albumin for half-life extension, and a single-chain fragment variable specific for the CD3ε subunit of the T-cell receptor complex for T-cell engagement. HPN328 redirects T cells to specifically and potently kill DLL3-expressing SCLC cells in vitro. In an immunocompetent mouse model expressing a human CD3ε epitope (hCD3ε mice), HPN328 induced potent anti-tumor activity and long-term immune memory confirmed by tumor rechallenge studies. HPN328 exhibits a favorable pharmacokinetic and safety profile in cynomolgus monkeys.

Materials and Methods

Protein production and purification

Expression constructs were generated for extracellular domains of human and cynomolgus monkey DLL3, as well as human, cynomolgus monkey, and mouse CD3ε, each fused to human Fc using pCDNA 3.4 (Life Technologies, A14697) or pINFUSE-hIgG1-Fc1 (InvivoGen) as DNA vector backbones. Fusion proteins were expressed in Expi293F cells using ExpiFectamine according to kit protocols (Life Technologies). Unless noted otherwise, DLL3-targeting TriTAC expression constructs were made and protein production was performed as described previously (18). HPN328 was expressed by generation of stable CHO-DG44 cell pools containing an expression vector with HPN328 coding sequence using the CHEF-1 expression system (AGC Biologics). Protein was purified from conditioned medium by protein A affinity, desalting, and mixed-mode ion-exchange chromatography or strong cation exchange chromatography and was subsequently formulated in appropriate buffers and excipients. Protein purity and quality were assessed by denaturing SDS-PAGE (Life Technologies) and analytical size-exclusion chromatography (high-performance liquid chromatography) using Yarra SEC-2000, SEC-X150, or SEC-X300 columns or BEH SEC 200 columns resolved on Agilent 1200 or 1290 LC systems and analyzed using ChemStation software. Sequences are provided in Example 5 of reference PCT/US2019/053017, published as WO 2020/069028 (20).

In vitro binding affinity measurements

Affinities of HPN328 for albumin, CD3ε, and DLL3 ligands were measured by biolayer interferometry using an Octet RED96 instrument with streptavidin tips (Pall ForteBio). Experiments were performed at 27°C in PBS plus casein in the absence or presence of 15 mg/mL human serum albumin (HSA) as described in “Results” and figure legends (Supplementary Figs. S4–S7). Binding sensorgrams generated from empirically determined ligand loads, appropriate serial dilutions of known analyte concentrations, and association and dissociation times were then fit globally to a one-to-one binding model using Octet Data Analysis 9.0 software.

Cell lines

All cancer cell lines were obtained from the ATCC. Cancer cell lines were transduced with firefly luciferase lentivirus with puromycin selection marker (Biosettia GlowCell-14p) and were selected by the addition of puromycin. Cell lines were passaged a maximum of 36 times after being received from the ATCC. Cell line authentication and Mycoplasma testing were not performed.

MC38 cells that stably express hDLL3 or hEGFR were transduced with the lentivirus vector encoding the respective human antigen (i.e., hDLL3, hEGFR) with puromycin selection marker and were selected by the addition of puromycin. Single-cell clones were then generated. Healthy donor T cells were purified from Leukopaks (leukapheresis samples, STEMCELL Technologies) using the EasySep Human T Cell Isolation Kit (STEMCELL Technologies), following the manufacturer’s instructions.

In vitro T cell–dependent cell cytotoxicity and T-cell activation assays

For T cell–dependent cell cytotoxicity (TDCC) assays (21), target cells were engineered to express luciferase, and purified primary resting human T cells were seeded in a 384-well plate at a 10:1 T-cell-to-target-cell ratio. Target cell viability was assessed following incubation for 48 hours at 37°C and 5% CO2. Because TriTACs contain an albumin-binding domain for half-life extension and are expected to be bound to albumin in serum and tissue when dosed in humans, a TDCC assay was conducted in the presence of 15 mg/mL HSA to simulate the in vivo conditions.

Target cell viability was assessed by incubation with the Steady-Glo reagent (Promega). Luminescence was measured using a PerkinElmer EnVision detection system. The gating strategy for T-cell activation assay was CD3/CD69 and CD3/CD25. The expression of CD3, CD69, and CD25 on T cells was measured by using flow cytometry with anti-CD3 clone SP34-2, anti-CD25 clone M-A251, and anti-CD69 clone FN50 antibodies (BD Biosciences). The samples were analyzed on FACSCelesta (BD Biosciences). Flow cytometry data were processed using FlowJo v10 software (FlowJo, LLC).

Binding of HPN328 on SCLC cells and T cells

Cultured cells or purified human T cells were incubated with HPN328 or anti-GFP TriTAC (control) for 1 hour. Binding was detected by using Alexa Fluor 647 anti-TriTAC antibody in a FACSCelesta flow cytometer (BD Biosciences).

In vitro cytokines detection in the presence of T cells

To measure cytokines, a commercially available electrochemiluminescence assay was used per the manufacturer’s instructions (Meso Scale Discovery V-PLEX Proinflammatory Panel 1 Human Kit, K15049D). Plates containing conditioned media from TDCC assays were used for cytokine analyses. Plates were read on a MESO SECTOR S 600 plate reader (Meso Scale Discovery).

hCD3ε mouse cell line generation

hCD3ε mice were developed and bred by genOway. Six amino acids corresponding to the human epitope to which TriTAC molecules bind were added to exon 4 of the mouse Cd3e locus, resulting in human/mouse chimeric CD3ε cDNA under the control of the endogenous mouse Cd3e promoter. Embryonic stem cells carrying the human/mouse chimeric Cd3e locus were validated by PCR and sequencing. Chimeras were generated by the injection of embryonic stem cells into blastocysts and subsequent breeding. Following colony generation, hCD3ε syngeneic mouse lines were maintained at Charles River Laboratories.

In vivo mouse efficacy studies

All mouse studies were performed in accordance with the policies and approved by the Institutional Animal Care and Use Committee at Harpoon Therapeutics, Inc. For the SHP-77 experiment, NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice received subcutaneous co-implants of SHP-77 cells (1 × 107) and ex vivo expanded human T cells (5 × 106) in 50% Matrigel (BD Biosciences) on day 0. Mice were dosed on days 1 to 10 via i.p. injection. For NCI-H82 experiments, NSG mice received subcutaneous implants of 5 × 106 cancer cells in 50% Matrigel on day 0. On day 8, when tumors reached approximately 168 mm3, the mice were randomized and injected intraperitoneally with ex vivo expanded human T cells (2 × 107). Treatment was initiated the following day by i.p. injection, from days 9 to 18. The tumor size was measured twice weekly and calculated using the following formula: tumor volume (mm3) = (width2 × length)/2. Percent tumor growth inhibition was defined as the difference between the mean tumor volume (MTV) of the control group and the MTV of the treated group, expressed as a percentage of the MTV of the control group.

For syngeneic studies, MC38, MC38-hDLL3, and MC38-hEGFR cells were implanted with 2 × 106 cancer cells in 50% Matrigel on day 0. For MC38-hEGFR studies, treatment was initiated the following day by i.p. injection for 10 days. For MC38-hDLL3 studies, when the average tumor size reached approximately 250 mm3, the mice were randomized. Treatment was initiated the following day by i.p. injection for 10 days. For rechallenge studies, when tumors fully receded, MC38 cells were implanted on the opposite flank on study day 30. An additional set of naïve mice that had not been previously treated were implanted on the same flank as that of the rechallenge mice as a control. Tumors from treated mice were minced with razor blades and further homogenized using a Mouse Tumor Dissociation Kit and gentleMACS Octo Dissociator (Miltenyi Biotec). Homogenized tumor cell samples were then run through a 70-µm cell strainer (Miltenyi Biotec). The cell suspensions were washed with FACS buffer (PBS + 2% FBS), blocked with Mouse Fc block (Tonbo), and surface stained with 2.5 µg/mL of antibody in FACS buffer for 30 minutes on ice. Flow data acquisition was performed with a FACSCelesta (BD Biosciences), and the data were analyzed using FlowJo (FlowJo). Markers and antibodies used for immunophenotyping experiments can be found in the Supplementary Tables S1 and S2.

IHC analysis

Mouse tumors were harvested at day 6 post dose, fixed overnight in 4% neutral buffered formaldehyde, then stored in 70% ethanol until embedded in paraffin. IHC staining was performed using the Ventana Discovery Ultra autostainer by UCSF Histology and Biomarker Core. NCI-H82 tumors were stained with anti-human CD3 (Ventana 2GV6), anti-human CD4 (Ventana SP35), or anti-human CD8 (Ventana SP57).

Good Laboratory Practice repeat-dose studies in cynomolgus monkey

The pharmacology, pharmacokinetics, and toxicity of HPN328 were evaluated after repeated intravenous bolus doses once weekly for 4 weeks (study days 1, 8, 15, 22) of the vehicle or 1 or 10 mg/kg HPN328 in 5 male and 5 female cynomolgus monkeys per group followed by either a 1- or 4-week post-last-dose recovery period. The study followed the Institutional Animal Care and Use Committee–approved protocol and standard operating procedures of the testing facility (Charles River Laboratories). Pharmacologic activity based on the hypothesized mechanism of action for HPN328 was evaluated by serum cytokine assessments and flow cytometry. A ligand-binding electrochemiluminescence assay, measuring functional interaction between HPN328 and its targets, was used for measuring HPN328 levels in the serum. HPN328 was captured with biotinylated recombinant CD3ε and detected with a sulfo-tagged recombinant DLL3. Toxicokinetic parameters were estimated using Phoenix WinNonlin software. A ligand-binding electrochemiluminescence assay was used to detect anti-HPN328 antibodies [anti-drug antibodies (ADA)] in the serum following drug exposure. A non-compartmental approach consistent with the intravenous bolus route of administration was used for parameter estimation. Safety and toxicity endpoints included daily morbidity and mortality, daily clinical observations, weekly body weights, daily food consumption, clinical pathology (hematology, clinical chemistry, and coagulation), and anatomic pathology (gross necropsy, organ weights, and histopathology).

Statistics

Statistical analyses were performed using Prism software (GraphPad). One-way ANOVA followed by Tukey’s post hoc test was applied where noted.

Data availability

The data generated in this study are available within the article and its supplementary data files.

Results

Structure and cytotoxic activity of HPN328

Built upon the TriTAC platform that has been previously described (18, 19), HPN328 is a DLL3-targeting T-cell engager with extended half-life via serum albumin binding. It is produced as a single-chain polypeptide with a molecular weight of approximately 50 kDa, consisting of a humanized single-chain fragment variable specific for the human CD3ε subunit of the T-cell receptor complex, a humanized llama sdAb specific for HSA, and a humanized llama sdAb selective for human DLL3 (Supplementary Fig. S1). HPN328 protein is pure as demonstrated by SDS-PAGE analysis (Supplementary Fig. S2A). Stability studies subjecting HPN328 to various stress conditions suggest that the protein is stable and stress resistant (Supplementary Fig. S2B).

Because TriTAC molecules consist of three domains, they can be made in six configurations. We previously observed that EGFR-targeting and prostate-specific membrane antigen–targeting TriTACs in the anti-target:anti-albumin:anti-CD3 (T:A:C) configuration were most potent in directed T-cell killing assays (18). In screening anti-DLL3 TriTACs made in different configurations, we observed that a molecule in the anti-CD3:anti-albumin:anti-DLL3 (C:A:T) configuration was more potent than a molecule in the T:A:C configuration. To confirm this result, TDCC assays were performed to confirm this potency difference. In co-cultures of DLL3-expressing NCI-H82, SHP-77, DMS 53, and NCI-H2171 SCLC cells and resting T cells from four different donors, the EC50 values in the C:A:T configured TriTACs (Fig. 1A and B; Supplementary Fig. S3; Supplementary Table S3) were on average 3.1-fold more potent than the EC50 values in the T:A:C configured TriTACs (Supplementary Table S4). Based on these data, HPN328 is configured in the C:A:T configuration.

Figure 1. HPN328 directs T-cell killing in the presence of DLL3-expressing cells. Luciferase-labeled tumor cells were incubated with resting human T cells from four different donors at a 1:10 target-to-T-cell ratio. Titrations of HPN328 or a negative control, anti-GFP TriTAC protein, were added to the target cell/T-cell co-cultures. About 48 hours later, the viability of tumor cells was assessed by measuring luciferase activity. A, DLL3-expressing NCI-H82 SCLC cells, (B) DLL3-expressing SHP-77 SCLC cells, (C) DLL3-negative HCT116 colon cancer cells, (D) HEK 293 cells engineered to express cynomolgus DLL3. Plotted are mean viability values ± SEM, n = 3.

HPN328 efficiently directed T cells to lyse SCLC target cells with EC50 values ranging from 16 to 286 pmol/L (Fig. 1A and B; Supplementary Fig. S3; Supplementary Table S3) with one donor cell line pair (NCI-H2171 combined with donor 86) failing to reach 50% killing. Specificity of DLL3 targeting by HPN328 was supported by the observation that the control TriTAC targeting GFP was unable to kill these cell lines, and HPN328 was inactive with cell lines that lacked DLL3 expression, HCT116, and NCI-H292 (Fig. 1C; Supplementary Fig. S3; Supplementary Table S3).

Binding affinity, specificity, and species cross-reactivity of HPN328

HPN328 binds with high affinity to human and cynomolgus monkey DLL3, CD3ε, and albumin in the range of 0.13 to 28 nmol/L (Supplementary Figs. S4 and S5) as assessed by biolayer interferometry. The KD values for binding of HPN328 to mouse DLL3 and ALB were 10.3 and 436 nmol/L, respectively, but did not detectably bind mouse CD3ε (Supplementary Fig. S6). The KD values for binding to human and cynomolgus orthologs were found to be highly similar for all three target antigens identifying cynomolgus monkeys as a relevant toxicological species. To confirm binding to cynomolgus DLL3 (cyDLL3) with a functional assay, HEK 293 cells genetically engineered to express cyDLL3 were incubated with cynomolgus monkey peripheral blood mononuclear cells in the presence of HPN328 killed with an EC50 value of 26 pmol/L (Fig. 1D). Combined with HPN328 binding (Supplementary Fig. S5), these data further confirm the target specificity of HPN328 and support the use of cynomolgus monkey as a relevant species to evaluate the on-target effects of HPN328 in toxicology studies.

To assess the selectivity of HPN328 for DLL3 over other delta-like ligand family members, biolayer interferometry was used to determine the binding kinetics and affinity of HPN328 to human (hu) DLL1 and DLL4. There was no detectable binding of HPN328 to huDLL1 (Supplementary Fig. S7). HPN328 was observed to bind to huDLL4 with a KD of 23 ± 1 nmol/L, indicating a 175-fold lower binding affinity to huDLL4 than to huDLL3 (Supplementary Fig. S7). Since cynomolgus monkey is a relevant toxicological species, the ability of HPN328 to bind to both cynomolgus (cy) DLL3 and DLL4 was also compared. HPN328 was observed to bind to cyDLL3 with a KD of 0.59 ± 0.02 nmol/L and to cyDLL4 with a KD of 14 ± 0.1 nmol/L (Supplementary Fig. S5), within five-fold and two-fold of the affinity of HPN328 for huDLL3 and huDLL4, respectively (Supplementary Figs. S4 and S7).

Flow cytometry was used to confirm the biolayer interferometry findings. HPN328 exhibited surface binding to human DLL3-expressing NCI-H82 SCLC cells and purified human T cells from two different donors (Supplementary Fig. S8A and S8B), confirming that HPN328 recognized native DLL3 and CD3ε expressed on cells. Furthermore, HPN328 was unable to bind DLL3-negative HCT 116 cells (Supplementary Fig. S8A).

HPN328-mediated T-cell activation

When binding to both T cells and DLL3-expressing cells, HPN328 is expected to activate T cells. To confirm T-cell activation, induction of CD69 and CD25 surface expression on T cells was measured. T cells from four healthy donors were co-cultured with DLL3-positive NCI-H82 or SHP-77 SCLC cell lines (Fig. 2A and B; Supplementary Fig. S9). Depending on the T-cell donor, between 5% and 25% of the T cells in culture upregulated CD69 and CD25 surface expression and were dependent on the amount of HPN328 present. A control TriTAC targeting GFP did not increase CD69 or CD25 expression on T cells. In addition, cells that lacked DLL3 expression, HCT116 (Supplementary Fig. S10), failed to increase CD69 or CD25 expression on T cells following the addition of HPN328. The EC50 values of HPN328 for upregulation of CD69 and CD25 in the presence of DLL3-positive cancer cells ranged from 23 to 1,304 pmol/L (Supplementary Tables S5 and S6).

Figure 2. HPN328 directs T-cell activation and mediates cytokine secretion in the presence of DLL3-expressing cells. Tumor cells were incubated with resting human T cells. Titrations of HPN328 or a negative control, anti-GFP TriTAC protein, were added to the target cell/T-cell co-cultures. About hours later, the expression of CD25 and CD69 were measured by flow cytometry. T cells from four different donors were incubated with DLL3-positive NCI-H82 SCLC cells, CD25 (A) and CD69 (B). Plotted is the expression of CD69 or CD25 on CD3+ T cells (±SEM, n = 2). In a follow-up experiment, resting T cells from Donor 81 were incubated with DLL3-positive NCI-H82 SCLC cells as described above. About 48 hours later, the cytokine levels were measured in the conditioned media collected from the co-cultures, IFNγ (C) or TNF⍺ (D). Plotted are the mean cytokine values (±SEM, n = 3).

The release of inflammatory cytokines was also used to assess T-cell activation from T cells co-cultured with DLL3-expressing cancer cells. HPN328 mediated a dose-dependent secretion of TNFα and IFNγ into media from NCI-H82 and SHP-77 co-cultures (Fig. 2C and D; Supplementary Table S7), indicative of T-cell activation. A control TriTAC targeting GFP did not cause cytokine release by T cells (Fig. 2C and D) nor were cytokines released from T cells in the co-culture with DLL3-negative tumor cell lines HCT116 (Supplementary Fig. S11), further confirming that HPN328 is DLL3 specific.

HPN328 mediates potent anti-tumor activity in mouse xenograft models

The anti-tumor activity of HPN328 was assessed in two xenograft mouse models established from SCLC that expresses DLL3. In a first study, SHP-77 tumor cells were subcutaneously co-implanted with ex vivo expanded T cells from a normal human donor at an effector-to-target cell ratio of 1:2 into NSG mice (Fig. 3A). A daily dosing regimen was used because previous work with an EGFR-targeting TriTAC molecule was determined to have a serum half-life of 15 to 18 hours (18). Daily doses of HPN328 of 100, 10, or 1 µg/kg were administered over 10 days by i.p. injection starting 1 day after implantation. Doses of 10 and 100 µg/kg HPN328 prevented SHP-77 tumor growth, although 1 µg/kg did not affect tumor growth (Fig. 3A) when compared with a control anti-GFP TriTAC at 100 µg/kg.

Figure 3. HPN328 potently inhibits the growth of SCLC xenografts. A, SHP-77 and T cells expanded from a healthy donor were co-implanted on day 0 at an effector-to-target-cell ratio of 1:2 and treated with HPN328 (1, 10, or 100 µg/kg) or anti-GFP TriTAC (100 µg/kg) on days 1–10 (n = 10). B, 5e6 NCI-H82 cells were injected subcutaneously on day 0. Mice were randomized on day 8 when tumors reached 168 mm3, and 2e7 T cells expanded from a healthy donor were injected intraperitoneally. Treatment with HPN328 (1, 10, or 100 µg/kg) or anti-GFP TriTAC (100 µg/kg) was initiated the following day by i.p. injection on days 9–18. n = 10. Upward pointing arrows indicate dosing. One-way ANOVA followed by Tukey’s post hoc test using GraphPad Prism software was used for statistical analyses. Plotted are mean tumor volumes ± SEM. C, Representative IHC images (human CD3, CD4, or CD8, brown staining) of NCI-H82 xenograft tumors at day 6 post dose (100 µg/kg anti-GFP TriTAC or 100 µg/kg HPN328).

In a second SCLC tumor model, NSG mice were injected subcutaneously with 5 × 106 NCI-H82 cells. When tumors reached an average of ∼170 mm3, 2 × 107ex vivo expanded T cells from a normal human donor were implanted by i.p. injection. Mice were treated for 10 days with 1, 10, and 100 µg/kg HPN328 from 1 day since implantation with human T cells. On day 24 post tumor implantation, 10 and 100 µg/kg HPN328 resulted in significant tumor growth inhibition of 61% and 96%, respectively, when compared with control anti-GFP TriTAC–treated mice (Fig. 3B). On day 6 post treatment, three tumors were collected from the 100 µg/kg anti-GFP TriTAC–treated and 100 µg/kg HPN328-treated groups and processed for IHC analysis of human CD3, CD4, and CD8 (Fig. 3C; Supplementary Fig. S12). The HPN328-treated mice showed extensive T-cell recruitment of both CD4- and CD8-positive cells on day 6 post treatment compared with no T-cell recruitment in the anti-GFP TriTAC–treated group. These results demonstrate the activity of HPN328 in recruiting T cells and controlling the growth of established DLL3-expressing SCLC tumors.

To assess the activity of HPN328 in an immunocompetent mouse model, we generated a mouse strain in which six amino acid residues corresponding to the portion of human CD3ε that binds to TriTAC molecules were added to the mouse CD3ε subunit (Supplementary Fig. S13A). Lymphocyte populations in the spleens of homozygous knock-in mice (hCD3ε) were compared with wild-type (WT) mice using flow cytometry. Compared with WT mice, hCD3ε mice demonstrated equal prevalence of T cells, B cells, CD4+ and CD8+ T cells, NK cells, macrophages, and dendritic cells (Supplementary Fig. S13B–S13D, respectively). As expected, flow cytometry analysis revealed that T cells from homozygous hCD3ε mice express both human and mouse CD3 (Supplementary Fig. S13E) and bind anti-EGFR–targeting TriTAC molecule (Supplementary Fig. S13F). T cells from hCD3ε mice could also be activated ex vivo by incubation with anti-human CD3 and anti-mouse CD28 beads, as demonstrated by proliferation (Supplementary Fig. S14A) and release of IL-2 and IFNγ (Supplementary Fig. S14B and S14C, respectively). Next, we evaluated the in vitro cytotoxic activity of hCD3ε T cells against MC-38 murine tumor cells engineered to express human EGFR (MC38-hEGFR). Following ex vivo activation and expansion, in a TDCC assay, hCD3ε T cells from hCD3ε mice were able to potently kill MC38-hEGFR cells in the presence of an anti-hEGFR–targeting TriTAC molecule (Supplementary Fig. S15A). Together demonstrating that T cells from hCD3ε mice can bind and exert cytotoxic activity in the presence of TriTAC molecules in vitro.

To further validate T-cell activity in the hCD3ε model, we next assessed TriTAC activity in vivo in this model. Homozygous hCD3ε or WT C57BL/6 mice were injected subcutaneously with 2 × 106 MC38-hEGFR cells. Daily doses of anti-hEGFR TriTAC or control anti-GFP TriTAC of 1 mg/kg were administered over 10 days by i.p. injection, starting 1 day after implantation. As expected, no activity was observed in WT mice treated with anti-hEGFR TriTAC (Supplementary Fig. S15B). Anti-hEGFR TriTAC treatment induced a strong anti-tumor response compared with the control anti-GFP TriTAC at 1 mg/kg indicating that the TriTAC molecules can engage and activate T cells in hCD3ε mice.

After confirming that hEGFR TriTAC molecules exhibit cytotoxic activity against murine syngeneic tumor line expressing human EGFR in vivo, we evaluated the activity of HPN328 against MC38 cells engineered to express human DLL3 (MC38-hDLL3) in the hCD3ε mouse model. HPN328 exhibited surface binding to the MC38-hDLL3 cell line (Supplementary Fig. S16). Mice received s.c. injection of 2 × 106 MC38-hDLL3 cells, and tumors grew to ∼215 mm3 before daily doses of 8, 40, 100, and 200 µg/kg of HPN328 or the vehicle were administered over 10 days by i.p. injection. HPN328 exhibited a dose-dependent anti-tumor response with 40 and 100 µg/kg leading to partial tumor growth inhibition and 200 µg/kg completely eradicating tumors (nine of nine mice were cured) when compared with vehicle-treated mice (Fig. 4A). To confirm that HPN328 is indeed activating and engaging intratumoral T cells, a follow-up experiment as shown in Fig. 4A was performed, in which we dissociated tumors following treatment with two doses of 100 µg/kg HPN328 or vehicle and performed FACS analysis. HPN328 treatment led to increases in CD25 and CD69 on CD8+ T cells (Fig. 4B).

Figure 4. Long-term anti-tumor immunity induced by HPN328 in an immunocompetent hCD3ε mouse model. A, 2e6 MC38-hDLL3 cells were implanted subcutaneously into hCD3ε mice and treated with HPN328 (8, 40, 100, or 200 µg/kg) or vehicle on days 9–18 (n = 9). Plotted are mean tumor volumes ± SEM. B, Percentage of CD69 and CD25 of CD8-positive T cells in tumors at 2 days post dose (100 µg/kg HPN328 or vehicle). *, P < 0.05. Plotted are values from individual tumors ± SEM. C, Schematic for rechallenge study design. D, 2e6 MC38-hDLL3 cells were implanted subcutaneously into hCD3ε mice and treated with HPN328 (100, 200, or 1,000 µg/kg) or vehicle on days 8–17 (n = 20). Plotted are mean tumor volumes ± SEM. E, Mice previously cured from (D) were rechallenged with 2e6 parental MC38 tumor cells on study day 30. F, On study day 60, the spleens from mice in (E) were processed and memory T cells were analyzed by flow cytometry. **, P < 0.01; ****, P < 0.0001. One-way ANOVA followed by Tukey’s post hoc test using GraphPad Prism software was used for statistical analyses. Plotted are mean ± SEM.

HPN328 induces long-term anti-tumor immunity

To evaluate whether mice treated with HPN328 developed anti-tumor immunity, hCD3ε mice implanted with MC38-hDLL3 tumors were treated with 100, 200, or 1,000 µg/kg HPN328 to elicit an anti-tumor response (Fig. 4C and D), although study-to-study variability in the anti-tumor activity of HPN328 in the hCD3ε syngeneic model has been observed (Fig. 4A and D). On study day 30, mice with no residual disease (7 mice from 200 µg/kg and 10 mice from 1,000 µg/kg groups) were rechallenged by implantation of parental MC38 cells on the opposite flank. Nine age-matched naïve mice were also implanted with parental MC38 cells as a control. On study day 57, 27 days post rechallenge with parental MC38 tumors, mice previously treated and cured with 200 µg/kg HPN328 exhibited slower tumor regrowth than naïve animals (Fig. 4E). By contrast, significant anti-tumor activity upon rechallenge was observed in mice previously cured from the 1,000 µg/kg HPN328, suggesting the development of immune memory. The spleens from mice were collected on study day 60 and processed for memory T cells. A dose-responsive increase in the CD8+ memory T-cell population was observed in the 200 and 1,000 µg/kg HPN328-treated mice when compared with naïve control animals (Fig. 4F). HPN328-cured mice successfully rejected tumor rechallenge with hDLL3-negative parental MC38 tumor cells with concomitant increases in memory T-cell populations, demonstrating that HPN328 can promote immunological memory and long-term anti-tumor immunity.

Pharmacokinetics of HPN328 in cynomolgus monkeys

The pharmacokinetics of HPN328 was evaluated in cynomolgus monkeys based on species cross-reactivity of HPN328 to cynomolgus DLL3, CD3, and albumin (see Supplementary Figs. S4 and S5), with functional cross-reactivity of HPN328 validated by the targeted lysis of cyDLL3-expressing HEK 293 cells (see Fig. 1D). A repeat dose of 1 or 10 mg/kg HPN328 was administered on study days 1, 8, 15, and 22, and a functional assay (recombinant CD3 and DLL3 proteins used for capture and detection, respectively) was used for detection of HPN328. Following the first dose of HPN328, concentrations of HPN328 declined biphasically (Fig. 5). Cmax and AUC values for HPN328 increased dose proportionally from 1 to 10 mg/kg (Supplementary Table S8). Following four weekly i.v. bolus injections, HPN328 Cmax increased dose proportionally, whereas AUC increased slightly more than dose proportionally with limited HPN328 accumulation at 1 mg/kg/dose and approximately 2.5-fold accumulation at 10 mg/kg/dose. The volume of distribution was independent of the dose. The mean half-life ranged from 78 to 187 hours (Supplementary Table S8), confirming half-life extension due to the presence of the anti–albumin-binding domain. Of the 10 animals dosed per group, ADAs to HPN328 were detected in 7 of 10 animals in the 1 mg/kg/dose group and in 3 of 10 animals in the 10 mg/kg/dose group. The presence of ADAs impacted HPN328 systemic exposure on day 22 for 3 ADA-positive animals at 1 mg/kg/dose and 1 ADA-positive animal at 10 mg/kg/dose. Although ADA was observed in both the 1 mg/kg and 10 mg/kg treatment groups, the mean systemic exposure (AUC0–168hr) on day 22 was similar when all data from all animals were compared with the systemic exposure from ADA-negative animals. Immunogenicity of humanized antibodies is expected in non-human primates (NHPs) and is not predictive of ADA in humans (22). As for any therapeutic, the potential occurrence or impact of ADAs would be closely monitored in patients during clinical development.

Figure 5. Repeat doses of HPN328 were well tolerated and exhibited half-life extension in cynomolgus monkeys. HPN328 serum concentrations after intravenous bolus doses of 1 or 10 mg/kg HPN328 was administered on study days 1, 8, 15, and 22 to cynomolgus monkeys (1 mg/kg ADA negative, n = 3; 1 mg/kg ADA positive, n = 7; 10 mg/kg ADA negative, n = 7; 10 mg/kg ADA positive, n = 3. Direction of error bars: above symbol for ADA negative, below symbol for ADA positive). An electrochemiluminescence ligand-binding assay was used to detect anti-HPN328 antibodies (ADA) in the serum following drug exposure. To detect HPN328, HPN328 was captured with biotinylated CD3ε and subsequently detected with a sulfo-tagged DLL3. Plotted are mean ± SEM.

Pharmacodynamics of HPN328 in cynomolgus monkeys

Multiple doses of HPN328 were well tolerated in cynomolgus monkeys up to 10 mg/kg. Consistent with T-cell activation and CD3 engagement by HPN328, transient reductions in T-cell subsets were also observed in response to HPN328 treatment (Supplementary Fig. S17A and S17B). Compared with vehicle-treated animals, there were also transient changes in counts of total lymphocytes and neutrophils associated with the first dose of HPN328 to cynomolgus monkeys that returned to normal levels 24 to 72 hours post dose, indicating that HPN328 was well tolerated (Supplementary Fig. S18A and S18B).

The number of stimulated T cells and the potency of T-cell stimulation by T-cell engagers can induce cytokine release syndrome (CRS; ref. 23). Often the most severe cytokine release is experienced following the first dose and dampens following subsequent doses often referred to as the “first-dose effect” (24). On days 1, 8, and/or 22, both sexes at ≥1 mg/kg/dose had increases in IL-6, IL-10, IFNγ, and MCP-1 concentrations at 4 and/or 8 hours post dose, which typically, partially to fully resolved by 24 hours post dose. Increases in cytokines tended to be most pronounced on day 1, with a lessening of the post-dose responses on days 8 and 22. These changes were considered test article–related and indicative of a transient post-dose immune/inflammatory response (Fig. 6; Supplementary Fig. S19). The administration of subsequent doses of HPN328 (on study days 8, 15, 22) did not elevate cytokine levels, suggesting a “first-dose effect”. Together, these data suggest that HPN328 is well tolerated and, as expected, leads to transient T-cell activation in NHPs.

Figure 6. Repeat doses of HPN328 treatment in cynomolgus monkeys lead to transient and dose-dependent increases in cytokines. A, IL-6, (B) IL-10, (C) IFNγ, and (D) MCP-1 following HPN328 administration in male cynomolgus monkeys. Vehicle, 1 or 10 mg/kg/dose HPN328 was administered by slow bolus i.v. injection over 2–3 minutes once weekly for 4 weeks on study days 1, 8, 15, and 22 (n = 5/group). Plotted are mean ± SEM.

Discussion

HPN328 is a novel TriTAC molecule being developed for the treatment of patients with advanced cancers that express DLL3. Here, we demonstrate that HPN328 is highly potent and specific in redirecting T cells to kill DLL3-expressing tumor cells in vitro and in multiple SCLC mouse tumor models. Unlike other TriTACs, which are configured in the anti-target:anti-albumin:anti-CD3 (T:A:C) format (18, 19), we found the activity of HPN328 was enhanced in the anti-CD3:anti-albumin:anti-DLL3 (C:A:T) configuration. This difference in configuration seems to be unique to this DLL3-targeting TriTAC and may possibly reflect how the anti-DLL3 domain in HPN328 interacts with DLL3. In vitro, HPN328 treatment at picomolar concentrations leads to T-cell activation, cytokine release, and T-cell killing of SCLC cells. In vivo, HPN328 recruited systemically administered T cells to the tumor site in mice, leading to potent anti-tumor activity. HPN328 administration to cynomolgus monkeys was well tolerated with a serum half-life of 78 to 187 hours. The safety and efficacy of HPN328 is currently being evaluated in SCLC patients and in patients with other DLL3-expressing tumors (NCT04471727).

The clinical success seen with blinatumomab in the treatment of acute lymphoblastic leukemia (ALL; ref. 25), TECVAYLI for the treatment of multiple myeloma (26), and tebentafusp for the treatment of melanoma (27) has led to further interest in the development of T-cell engagers to treat various solid tumor types. High differential expression of DLL3 on tumor versus normal tissue makes it an attractive target for T-cell engagers. Tumors from SCLC patients showed DLL3 positivity in 1,040 of 1,362 or 76.4% of tumor specimens (6, 7). In addition to SCLC, DLL3 expression was also reported in various neuroendocrine tumors, including glioma (8), gastrointestinal neuroendocrine malignancies (10), small cell bladder cancer (11), Merkel cell carcinoma (28), and neuroendocrine prostate cancer (9).

A previous drug targeting DLL3-expressing tumors was unsuccessful in clinical trials. This drug, an anti-DLL3 antibody drug conjugate (ADC) called rovalpituzumab tesirine (Rova T), initially showed early clinical activity, but eventually, clinical development was halted due to dose-limiting toxicities attributed to the payload of the ADC (12). The mechanism through which ADC technologies function, such as Rova-T, differ greatly from that of T-cell engagers. The relatively low abundance of DLL3 on tumors may not be sufficient to deliver the payload required for ADCs to be effective at tolerated doses. On the other hand, only a very small number of sites likely need to be occupied by a T-cell engager such as HPN328 to kill cancer cells. The EC50 values for redirected lysis by HPN328 are a log lower than the KD values measured for HPN328 binding to DLL3 and CD3ε, suggesting that only a very few TriTAC molecules are needed for cytolytic synapse formation. Cytolytic synapses have been described for an epithelial cell adhesion molecule/CD3 bispecific T-cell engager molecule (29), and these serve as sites for T-cell activation followed by perforin and granzyme release and ultimately target cell lysis through caspase 3- and 7-mediated apoptosis (30). The mechanism through which T-cell engagers target tumor cells suggests that they may be more effective in treating DLL3-expressing cancers.

In a multiple-dose Good Laboratory Practice (GLP) study on cynomolgus monkeys, HPN328 was well tolerated at 10 mg/kg. This dose leads to circulating HPN328 levels that are 1,000- to 10,000-fold higher than its EC50 values determined by TDCC assays, suggesting a potentially large therapeutic window for HPN328. Both the 1 and 10 mg/kg doses led to transient reductions in circulating T cells consistent with the mechanism of action of TriTAC molecules.

Mitigating or managing the impact of cytokine release syndrome is an important aspect in the clinical management of T-cell engagers. In a repeat-dose study, cytokines in the serum of high dose–treated NHPs peaked between 6 and 8 hours and recovered to baseline values within 24 hours in most cases except for IL-6, which returned to baseline by day 8. The observation that cytokines did not spike again following the second, third, or fourth dose suggests that the transient increase in cytokines are related to the “first-dose effect” in which the most severe release of cytokines is observed after the first administration of the drug (24). Limiting the peak levels of proinflammatory cytokines by utilizing step-fractionated dosing in which a portion of the dose is given in a stepwise manner can be effective (23).

An additional challenge faced by T-cell engagers targeting solid tumors compared with liquid cancers is the relative lack of T cells within the tumor microenvironment. Here, by IHC, we show that HPN328 was able to recruit T cells to “cold” tumors that lead to an immunogenically active tumor microenvironment and anti-tumor activity. The ability of HPN328 to recruit T cells to the tumor may lead to wider immunological changes in the tumor microenvironment and be advantageous for patient outcomes.

The development of a mouse strain containing the epitope of hCD3ε on mouse T cells allows for investigation of TriTAC activity in an immunocompetent system. We demonstrate that T cells in this mouse model are functional and demonstrate cytotoxic anti-tumor activity in the presence of an anti-hEGFR TriTAC or HPN328. Rechallenge studies further demonstrate that HPN328 treatment has led to long-term anti-tumor immunity in the hCD3ε model. T-cell activation and cytokine release induced by TriTACs or other T-cell engagers have the potential to recruit and activate other immune cell types to the tumor microenvironment leading to epitope spreading and sustained anti-tumor immunity. Dao and colleagues (31) have provided evidence that T-cell engagers can induce epitope spreading in vitro. Epitope spread and this novel mechanism of anti-tumor activity induced by T-cell engagers can potentially contribute to efficacy seen in patients where intra- and inter-tumor heterogeneity may contribute to disease progression.

The stability and half-life of HPN328 in cynomolgus monkeys support a once weekly dosing regimen. The use of two sdAbs allow HPN328 to be highly stable while retaining its small size. The intrinsic stability of sdAbs compared with antibody fragments make them ideal for use in a T-cell engaging molecule (32, 33). For half-life extension, HPN328 relies on an sdAb that binds to HSA. In NHPs, the sdAb confers a prolonged half-life of 78 to 187 hours for HPN328 when compared with only 2 hours for the bispecific T-cell engager antibody blinatumomab, which requires continuous intravenous infusion (25, 34). The half-life of HPN328 observed in NHPs is consistent with other TriTAC molecules (18, 19) and supports a weekly or less frequent dosing schedule in patients.

The present study provides a clear rationale to assess the safety and tolerability of HPN328 in patients with advanced DLL3-expressing cancers. The purported mechanism of action, preclinical activity, and safety profile observed in cynomolgus monkeys following the administration of HPN328 all support the potential for a safe and effective therapy for patients whose tumors express DLL3. A phase 1/2 study of HPN328 as monotherapy to assess the safety, tolerability, and pharmacokinetics in patients with advanced cancers associated with DLL3 expression, including SCLC and other neuroendocrine malignancies is currently ongoing (NTC NCT04471727).

Supplementary Material

Supplementary Data Legend Legend for Supplementary Data

Figure S1 Structure of HPN328.

Figure S2 HPN328 purity and biophysical stability.

Figure S3 HPN328 directs T cell killing in the presence of DLL3 positive DMS 53 and NCI-H2171 cells.

Figure S4 Binding of HPN328 to DLL3, albumin and CD3e.

Figure S5 HPN328 binding cross-reactivity to cynomolgus monkey and mouse targets.

Figure S6 HPN328 binding cross-reactivity to mouse targets.

Figure S7 HPN328 binding selectivity to human DLL1 and human DLL4.

Figure S8 FACS Binding of HPN328 to DLL3+ cells and T cells.

Figure S9 HPN328 directs T activation in the presence of DLL3 expressing SHP-77 cells.

Figure S10 TDCC co-cultures show no T cell activation in the presence DLL3 negative tumor cell line.

Figure S11 TDCC co-cultures show no secretion of cytokines in the presence DLL3 negative tumor cell line.

Figure S12 IHC staining of NCI-H82 xenograft tumors.

Figure S13 Validation of the hCD3ε Mouse Syngeneic Cell line.

Figure S14 Stimulation with anti-human CD3 and anti-mouse CD28 beads induces proliferation and activation of T cells from hCD3ε mice.

Figure S15 TriTAC mediated cytotoxic activity in vitro and in vivo in the hCD3ε mouse model.

Figure S16 HPN328 binds to the MC38-hDLL3 cell line.

Figure S17 HPN328 treatment in cynomolgus monkeys leads to transient reduction in circulating T cells.

Figure S18 Transient changes in counts of white blood cells, lymphocytes, neutrophils, and monocytes associated with single dose intravenous administration of HPN328 to cynomolgus monkeys.

Figure S19 Repeat doses of HPN328 treatment in female cynomolgus monkeys leads to transient and dose dependent increases cytokines.

Table S1 Markers used for immunophenotyping hCD3ε syngeneic model.

Table S2 Antibodies used for immunophenotyping hCD3ε syngeneic model.

Table S3 EC50 Values from TDCC assays with anti-DLL3 TriTAC in the C:A:T Configuration (HPN328).

Table S4 EC50 Values from TDCC assays with anti-DLL3 TriTAC in the T:A:C Configuration.

Table S5 EC50 Values for HPN328 mediated induction of CD25.

Table S6 EC50 Values for HPN328 mediated induction of CD69.

Table S7 EC50 Values for HPN328 induced expression of TNF⍺ and IFNγ.

Table S8 Pharmacokinetic parameters for HPN328 dosed IV in cynomolgus monkeys.

Acknowledgments

All funding was provided by Harpoon Therapeutics, Inc.

Authors’ Disclosures

M.E. Molloy reports former employment at Harpoon Therapeutics, Inc. and owns shares of Harpoon Therapeutics. M. Barath reports employment at Harpoon Therapeutics, Inc. from December 2016 to November 2022 and, until recently, owning shares of Harpoon Therapeutics, Inc. M. Cremin reports employment at Harpoon Therapeutics, Inc. B.D. Lemon reports a patent for US 11,453,716 issued, a patent for US 11,623,958 issued, a patent for US 10,730,954 issued, a patent for US 10,844,134 issued, a patent for US 11,136,403 issued, a patent for WO-2021-163364-A1 pending, a patent for WO-2022-192225-A1 pending, and a patent for WO-2022-212732-A1 pending. L. Santiago reports employment at Harpoon Therapeutics, Inc. K.L. Strobel reports personal fees from Harpoon Therapeutics, Inc. and Engage Bio outside the submitted work. C.-L. Law reports personal fees from Harpoon Therapeutics, Inc. outside the submitted work and having a patent for combination therapy with immune cell–engaging proteins and immunomodulators pending. H. Wesche reports being an inventor of T cell Engager related patents and employment at Harpoon Therapeutics, Inc. R.J. Austin reports personal fees and other support from Harpoon Therapeutics, Inc., outside the submitted work and having a patent for US10815311B2 issued. No disclosures were reported by the other authors.

Authors’ Contributions

M.E. Molloy: Conceptualization, data curation, formal analysis, methodology, writing–original draft. W.H. Aaron: Conceptualization, data curation, formal analysis, supervision, investigation, methodology. M. Barath: Investigation. M.C. Bush: Investigation. E.C. Callihan: Investigation. K. Carlin: Investigation. M. Cremin: Investigation. T. Evans: Investigation. M.G. Guerrero: Investigation. G. Hemmati: Investigation. A.S. Hundal: Investigation. L. Lao: Investigation. P. Laurie: Investigation. B.D. Lemon: Conceptualization, formal analysis, supervision. S.J. Lin: Conceptualization, investigation, methodology. J. O’Rear: Investigation. P. Patnaik: Investigation. S. Sotelo Rocha: Formal analysis, supervision, investigation, methodology. L. Santiago: Formal analysis, writing–review and editing. K.L. Strobel: Formal analysis, investigation. L.B. Valenzuela: Investigation. C.-H. Wu: Investigation. S. Yu: Investigation. T.Z. Yu: Formal analysis, investigation. B.S. Anand: Writing–review and editing. C.-L. Law: Conceptualization, formal analysis, supervision, writing–review and editing. L.L. Sun: Conceptualization, formal analysis, writing–original draft. H. Wesche: Conceptualization, resources, supervision, methodology. R.J. Austin: Conceptualization, formal analysis, supervision, methodology, writing–review and editing.

Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).
==== Refs
References

1. Sung H , FerlayJ, SiegelRL, LaversanneM, SoerjomataramI, JemalA, . Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71 :209–49.33538338
2. Pesch B , KendziaB, GustavssonP, JöckelK-H, JohnenG, PohlabelnH, . Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case–control studies. Int J Cancer 2012;131 :1210–9.22052329
3. Bunn PA Jr , MinnaJD, AugustynA, GazdarAF, OuadahY, KrasnowMA, . Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes? J Thorac Oncol 2016;11 :453–74.26829312
4. Yang S , ZhangZ, WangQ. Emerging therapies for small cell lung cancer. J Hematol Oncol 2019;12 :47.31046803
5. Saunders LR , BankovichAJ, AndersonWC, AujayMA, BheddahS, BlackK, . A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 2015;7 :302ra136.
6. Regzedmaa O , LiY, LiY, ZhangH, WangJ, GongH, . Prevalence of DLL3, CTLA-4 and MSTN expression in patients with small cell lung cancer. Onco Targets Ther 2019;12 :10043–55.31819500
7. Huang RSP , HolmesBF, PowellC, MaratiRV, TyreeD, AdmireB, . Delta-like protein 3 prevalence in small cell lung cancer and DLL3 (SP347) assay characteristics. Arch Pathol Lab Med 2019;143 :1373–7.30958693
8. Spino M , KurzSC, ChiribogaL, SerranoJ, ZeckB, SenN, . Cell surface notch ligand DLL3 is a therapeutic target in isocitrate dehydrogenase–mutant glioma. Clin Cancer Res 2019;25 :1261–71.30397180
9. Puca L , GavyertK, SailerV, ConteducaV, DardenneE, SigourosM, . Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med 2019;11 :eaav0891.30894499
10. Matsuo K , TaniguchiK, HamamotoH, ItoY, FutakiS, InomataY, . Delta-like 3 localizes to neuroendocrine cells and plays a pivotal role in gastrointestinal neuroendocrine malignancy. Cancer Sci 2019;110 :3122–31.31369178
11. Koshkin VS , GarciaJA, ReynoldsJ, ElsonP, Magi-GalluzziC, McKenneyJK, . Transcriptomic and protein analysis of small-cell bladder cancer (SCBC) identifies prognostic biomarkers and DLL3 as a relevant therapeutic target. Clin Cancer Res 2019;25 :210–21.30327311
12. Rudin CM , PietanzaMC, BauerTM, ReadyN, MorgenszternD, GlissonBS, . Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol 2017;18 :42–51.27932068
13. Giffin M , CookeK, LobenhoferE, FriedrichM, RaumT, CoxonA. P3.12-03 targeting DLL3 with AMG 757, a BiTE; antibody construct, and AMG 119, a CAR-T, for the treatment of SCLC. J Thorac Oncol 2018;13 :S971.
14. Morgensztern D , BesseB, GreillierL, Santana-DavilaR, ReadyN, HannCL, . Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase II TRINITY study. Clin Cancer Res 2019;25 :6958–66.31506387
15. Hipp S , VoynovV, Drobits-HandlB, GiragossianC, TrapaniF, NixonAE, . A bispecific DLL3/CD3 IgG-like T-cell engaging antibody induces antitumor responses in small cell lung cancer. Clin Cancer Res 2020;26 :5258–68.32554516
16. Giffin MJ , CookeK, LobenhoferEK, EstradaJ, ZhanJ, DeegenP, . AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res 2021;27 :1526–37.33203642
17. Johnson ML , ZvirbuleZ, LaktionovK, HellandA, ChoBC, GutierrezV, . Rovalpituzumab tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage–SCLC: results from the phase 3 MERU study. J Thorac Oncol 2021;16 :1570–81.33823285
18. Austin RJ , LemonBD, AaronWH, BarathM, CulpPA, DuBridgeRB, . TriTACs, a novel class of T–cell–engaging protein constructs designed for the treatment of solid tumors. Mol Cancer Ther 2021;20 :109–20.33203731
19. Molloy ME , AustinRJ, LemonBD, AaronWH, GantiV, JonesA, . Preclinical characterization of HPN536, a trispecific, T–cell–activating protein construct for the treatment of mesothelin-expressing solid tumors. Clin Cancer Res 2021;27 :1452–62.33262134
20. Wesche H , AustinRJ. DLL3 binding proteins and methods of use patent. US 10815311B2. 2020 Oct 27.
21. Nazarian AA , ArchibequeIL, NguyenYH, WangP, SinclairAM, PowersDA. Characterization of bispecific T-cell engager (BiTE) antibodies with a high-capacity T-cell dependent cellular cytotoxicity (TDCC) assay. J Biomol Screen 2015;20 :519–27.25477202
22. van Meer PJ , KooijmanM, BrinksV, Gispen-de WiedCC, Silva-LimaB, MoorsEH, . Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. MAbs 2013;5 :810–6.23924803
23. Shimabukuro-Vornhagen A , GödelP, SubkleweM, StemmlerHJ, SchlößerHA, SchlaakM, . Cytokine release syndrome. J Immunother Cancer 2018;6 :56.29907163
24. Klinger M , BrandlC, ZugmaierG, HijaziY, BargouRC, ToppMS, . Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012;119 :6226–33.22592608
25. Przepiorka D , KoC-W, DeisserothA, YanceyCL, Candau-ChaconR, ChiuH-J, . FDA approval: blinatumomab. Clin Cancer Res 2015;21 :4035–9.26374073
26. Dhillon S . Tebentafusp: first approval. Drugs 2022;82 :703–10.35364798
27. Kang C . Teclistamab: first approval. Drugs 2022;82 :1613–9.36352205
28. Xie H , KayeFJ, IsseK, SunY, RamothJ, FrenchDM, . Delta-like protein 3 expression and targeting in Merkel cell carcinoma. Oncologist 2020;25 :810–7.32372416
29. Offner S , HofmeisterR, RomaniukA, KuferP, BaeuerlePA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006;43 :763–71.16360021
30. d’Argouges S , WissingS, BrandlC, PrangN, LutterbueseR, KozhichA, . Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res 2009;33 :465–73.18835037
31. Dao T , PankovD, ScottA, KorontsvitT, ZakhalevaV, XuY, . Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nat Biotechnol 2015;33 :1079–86.26389576
32. Muyldermans S . Nanobodies: natural single-domain antibodies. Annu Rev Biochem 2013;82 :775–97.23495938
33. Dumoulin M , ConrathK, Van MeirhaegheA, MeersmanF, HeremansK, FrenkenLGJ, . Single-domain antibody fragments with high conformational stability. Protein Sci 2002;11 :500–15.11847273
34. Schlereth B , QuadtC, DreierT, KuferP, LorenczewskiG, PrangN, . T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother 2006;55 :503–14.16032400
